Zydus’ Sentynl pens $475M deal for Mereo’s phase 3-ready rare genetic lung disease drug

Sentynl Therapeutics has penned a deal potentially worth $475 million for the option to market Mereo BioPharma's phase 3-ready rare genetic respiratory disease drug in the U.S.